

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/367,052	08/06/1999	TADAMITSU KISHIMOTO	1422-386PCT	3818
2292	7590 08/11/2005		EXAMINER	
BIRCH STEWART KOLASCH & BIRCH			LUCAS, ZA	CHARIAH
PO BOX 747 FALLS CHUI	RCH, VA 22040-0747		ART UNIT	PAPER NUMBER
	•		1648	

DATE MAILED: 08/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
09/367,052	KISHIMOTO ET AL.	
Examiner	Art Unit	
Zachariah Lucas	1648	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED <u>25 July 2005</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:
a) X The period for reply expires 5 months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  NOTICE OF APPEAL
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).
<u>AMENDMENTS</u>
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below);
(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for

	appeal; and/or
	(d) They present additional claims without canceling a corresponding number of finally rejected claims.
	NOTE: (See 37 CFR 1.116 and 41.33(a)).
4. [	The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. 🛚	Applicant's reply has overcome the following rejection(s): See, continuation of 13 below.
6.	Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling
	the non-allowable claim(s).
7. 🛛	For purposes of appeal, the proposed amendment(s): a) 🔲 will not be entered, or b) 🔯 will be entered and an explanation o
	how the new or amended claims would be rejected is provided below or appended.
	The status of the claim(s) is (or will be) as follows:
	Claim(s) allowed:
	Claim(s) objected to: 29,30,32 and 33.
	Claim(s) rejected: 13,16,22,27,28,31 and 34.
	Claim(s) withdrawn from consideration:

## AFFIDAVIT OR OTHER EVIDENCE

B. [	$\square$ The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will <u>not</u> be enter	rec
	because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessar	у
	and was not earlier presented. See 37 CFR 1.116(e).	

- 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
- 10.  $\square$  The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

## REQUEST FOR RECONSIDERATION/OTHER

- 11.  $\square$  The request for reconsideration has been considered but does NOT place the application in condition for allowance because:
- 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s).
- 13. Other: See Continuation Sheet.

Note-attached Interview Summary August 5 and 8 2005 Continuation of 13. Other: The amendments to the claims to remove the language identified in paragraph 7 of the Final action overcomes the indefiniteness rejection of that paragraph.

The Applicant has amended claims 16, 29-31 to read on recombinant cells expressing heterologous murine fusin and human CD4 recptors. The amendments to these claims overcome the art rejections to these claims, and the enablement rejections of paragraphs 13 and 14 in the Final action with reference to these claims.

However, the amendments do not overcome the art rejection of claim 13 over the Nagasawa reference. Claim 13 and its dependent claims require only the expression of the murine receptor in a recombinant cell. Such is disclosed by this reference. See, pages 14727 (DNA transfections), and 14729 (left column, first full paragraph- each describing the making of hampster cells expressing the murine receptor). Further, the reference teaches the murine DNA and protein sequence as GenBank Accession D87747 (footnote page 14726), which sequence is identical to SEQ ID NO: 1. The rejection is therefore maintained with respect to claims 13, 27, and 28.

The enablment and written description rejections of claims 13, 16, 22, 24-27, 29, 31, 32, 34, and 35 in prargraphs 9 and 10 is maintained against pending claims 13, 16, 22, 31, and 34 for the reasons of record, and because the claims are still drawn to derivatives of SEQ ID NO: 1 (i.e. the hybridization partners to the complement of SEQ ID NO: 1). As was indicated in the interview of August 8, 2005, amendment of these claims to require that the hybridization partner is isolated from a murine cell would overcome this rejection.

Claims 29, 30, 32, and 33 are objected to as depending from rejected claims.

SUPERVISORY PATENT EXAMIN TECHNOLOGY CENTER 1600